CurveBeam AI Limited(CVB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

CVB.AU CurveBeam AI Limited

Closed 04-29 16:12:00 AEST

0.10

+0.00

-5.00%

High0.10	Low0.10	Vol338.64K
Open0.10	D1 Closing0.10	Amplitude5.00%
Mkt Cap37.07M	Tradable Cap28.03M	Total Shares390.16M
T/O32.63K	T/O Rate0.11%	Tradable Shares295.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CVB.AU","market":"AU","secType":"STK","nameCN":"CurveBeam AI Limited","latestPrice":0.095,"timestamp":1745907120000,"preClose":0.1,"halted":0,"volume":338639,"delay":0,"nameEN":"CurveBeam AI Limited","floatShares":295079621,"shares":390162030,"eps":-0.057222,"marketStatus":"Closed","change":-0.005,"latestTime":"04-29 16:12:00 AEST","open":0.1,"high":0.1,"low":0.095,"amount":32626,"amplitude":0.05,"askPrice":0.11,"askSize":136203,"bidPrice":0.095,"bidSize":34191,"shortable":3,"etf":0,"ttmEps":-0.057222,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745971200000},"marketStatusCode":5,"adr":0,"listingDate":1692626400000,"exchange":"ASX","adjPreClose":0.1,"openAndCloseTimeList":[[1745884800000,1745906400000]],"volumeRatio":2.973454,"lotSize":0,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/CVB.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2525488191","title":"CurveBeam AI Sees No Material Impact from US Tariffs; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2525488191","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525488191?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 10:52","pubTimestamp":1744080735,"startTime":"0","endTime":"0","summary":"CurveBeam AI  does not expect any material impact from the Trump administration's tariffs, saying most of the components it uses come from US partners, according to a Tuesday filing with the Australian bourse.The company, which makes point-of-care specialized medical imaging equipment, conducts its manufacturing activities within the US. The majority of components derived from its US partners represent around 75% of the cost of goods, per the filing.\"Based on an initial risk assessment, the company does not expect material adverse effects from the tariff changes,\" CurveBeam said in the filing.The company's shares were up 6% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","CVB.AU"],"gpt_icon":0},{"id":"2525885643","title":"BUZZ-Australia's CurveBeam AI rises as co fears no material impact from US tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2525885643","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525885643?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 10:18","pubTimestamp":1744078699,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CurveBeam AI rises as co fears no material impact from US tariffs     ** Shares of CurveBeam AI CVB.AX rise as much as 6.8% to A$0.094, their biggest intraday pct gain since March 31** The medical equipment manufacturer says that it expects no material impact from tariffs announced by U.S. President Donald Trump** Co highlights that it conducts majority of its manufacturing activities within the U.S.** Shares of co fell 16.2% on Monday, in line with the markets sell-off seen globally amid recession fears** Shares of CurveBeam down 31.1%, YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nL6N3QM059:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","CVB.AU"],"gpt_icon":0},{"id":"2525115002","title":"BRIEF-Curvebeam AI Expects No Material Adverse Effects From US Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2525115002","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525115002?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 09:25","pubTimestamp":1744075555,"startTime":"0","endTime":"0","summary":"BRIEF-Curvebeam AI Expects No Material Adverse Effects From US TariffsApril 8 (Reuters) - Curvebeam AI Ltd CVB.AX:EXPECTS NO MATERIAL ADVERSE EFFECTS FROM US TARIFFSFurther company coverage: CVB.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QL0ZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVB.AU","BK7007"],"gpt_icon":0},{"id":"2525008774","title":"Curvebeam AI Ltd - Expects No Material Adverse Effects From US Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2525008774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525008774?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 07:25","pubTimestamp":1744068335,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0ZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","CVB.AU"],"gpt_icon":0},{"id":"2518761059","title":"CurveBeam AI (ASX:CVB) Is Making Moderate Use Of Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2518761059","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518761059?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 07:41","pubTimestamp":1741736512,"startTime":"0","endTime":"0","summary":"Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-cvb/curvebeam-ai-shares/news/curvebeam-ai-asxcvb-is-making-moderate-use-of-debt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CVB.AU","BK7007","EBIT"],"gpt_icon":0},{"id":"2514806366","title":"BRIEF-Curvebeam AI Posts HY Revenues From Ordinary Activities A$4.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514806366","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514806366?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 09:36","pubTimestamp":1740706588,"startTime":"0","endTime":"0","summary":"BRIEF-Curvebeam AI Posts HY Revenues From Ordinary Activities A$4.9 MlnFeb 28  - Curvebeam AI Ltd CVB.AX:HY REVENUES FROM ORDINARY ACTIVITIES A$4.9 MILLIONLOSS AFTER INCOME TAX EXPENSE FOR HALF-YEAR ATTRIBUTABLE A$10.5 MILLIONFurther company coverage: CVB.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI1DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVB.AU"],"gpt_icon":0},{"id":"2514683358","title":"Curvebeam AI Ltd -   Loss After Income Tax Expense for Half-Year Attributable a$10.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514683358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514683358?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 05:19","pubTimestamp":1740691176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI1DI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","CVB.AU"],"gpt_icon":0},{"id":"2514358684","title":"Curvebeam AI Ltd - Hy Revenues From Ordinary Activities a$4.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514358684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514358684?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 05:19","pubTimestamp":1740691176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI1DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVB.AU","BK7007"],"gpt_icon":0},{"id":"2508161065","title":"The ASX medtech innovator positioned for growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2508161065","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508161065?lang=en_us&edition=full_marsco","pubTime":"2025-02-03 11:47","pubTimestamp":1738554461,"startTime":"0","endTime":"0","summary":"CurveBeam AI  listed on the ASX in August 2023 during a challenging period when the IPO market was firmly shut, start-ups globally had seen valuations crunched and healthcare was hard hit. CurveBeam was not immune to these market conditions, seeing its share price fall from A$0.48 per share down to lows of A$0.094.With all these positives, one may assume that CurveBeam must trade at a significant premium to its listed peers. It does not. With a market cap of just ~A$40m, CurveBeam trades at a significant discount. This valuation gap appears disconnected from the company’s robust fundamentals, including its market presence, clinical validation, and accelerating sales growth. As adoption expands, we believe the gap will narrow, offering substantial upside potential.CurveBeam AI is a medical device company on the cutting edge of orthopaedic imaging with its HiRise weight-bearing CT  system. The device addresses significa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-asx-medtech-innovator-positioned-for-growth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-asx-medtech-innovator-positioned-for-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4504","SYK","IPD.AU","LU2362541513.USD","GB00B4LPDJ14.GBP","LU1983299246.USD","LU2404859741.USD","LU0690374961.EUR","LU1791710400.SGD","LU2089984988.USD","LU2362540622.SGD","BK4585","CVB.AU","GB00B4QBRK32.GBP","BK4588","BK7007","LU2362541273.HKD","BK7509","BK4082","LU0882574055.USD","SFS","LU0690374615.EUR","LU0528227936.USD","LU2468319806.SGD","LU0114720955.EUR","BK4566","LU1791710582.SGD","LU2404859667.USD"],"gpt_icon":0},{"id":"2506559096","title":"CurveBeam AI Signs Commercial Deal with Medical Device Maker; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506559096","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506559096?lang=en_us&edition=full_marsco","pubTime":"2025-01-28 11:13","pubTimestamp":1738033987,"startTime":"0","endTime":"0","summary":"CurveBeam AI  signed a commercial agreement with medical device manufacturer Stryker Australia for the Australia and New Zealand markets, according to a Tuesday filing with the Australian bourse.Stryker will educate surgeons and promote the company's weight-bearing computed tomography imaging device HiRise for use in lower extremity orthopedic applications under the deal, the filing said.The agreement, with an initial term of three years and a further term of two years, requires minimum referral volumes for sales and commissions to continue, per the filing.CurveBeam AI shares were down 4% in afternoon trade Friday.Price : $0.11, Change: $-0.0050, Percent Change: -4.35%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426417589.USD","MKR.USD.CC","AUD","LU1043141123.HKD","XAO.AU","BK4125","LU0426412945.USD","MKR.USD.HKCC","CVB.AU","BK7007","LU0345774631.USD","XKO.AU","XJO.AU","LU0994945656.USD","LU2238339852.HKD"],"gpt_icon":0},{"id":"2506530873","title":"BRIEF-Curvebeam AI Says Commercial Agreement With Stryker Expanded To Australia & New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2506530873","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506530873?lang=en_us&edition=full_marsco","pubTime":"2025-01-28 09:04","pubTimestamp":1738026289,"startTime":"0","endTime":"0","summary":"BRIEF-Curvebeam AI Says Commercial Agreement With Stryker Expanded To Australia & New ZealandJan 28 (Reuters) - Curvebeam AI Ltd CVB.AX:COMMERCIAL AGREEMENT WITH STRYKER EXPANDED TO AUSTRALIA & NEW ZEALANDFurther company coverage: CVB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250128:nFWN3ON145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVB.AU","BK7007"],"gpt_icon":0},{"id":"2506533672","title":"Curvebeam AI  - Commercial Agreement With Stryker Expanded to Australia & New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2506533672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506533672?lang=en_us&edition=full_marsco","pubTime":"2025-01-28 06:11","pubTimestamp":1738015867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3ON145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","CVB.AU"],"gpt_icon":0},{"id":"2491503738","title":"There's more to Australian biotech than just CSL: the opportunities to watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2491503738","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491503738?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 04:09","pubTimestamp":1734293355,"startTime":"0","endTime":"0","summary":"Just a couple of years ago, CSL stood alone as Australia’s only profitable biotech company. Fast forward to today and the landscape has dramatically shifted, with Neuren and Telix delivering FDA approved products and becoming profitable. Botanix has also recently received FDA approval and is set to launch shortly, further enhancing the sector’s credibility.Several other companies including Opthea , Immutep and Dimerix are progressing through Phase 3 trials, while Syntara is set to potentially begin a Phase 3 trial in 2025, pending feedback from the FDA. The local ecosystem is starting to mature and is looking better and better.There are two competing schools of thought within the incoming US administration that are diametrically opposed on what direction the FDA should take. However, what remains certain is the continued need for robust drug and device development.In contrast to the US, Australia’s, regulatory environment is much more stable. The federal government is highly supportive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/there-s-more-to-australian-biotech-than-just-csl-the-opportunities-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["OPT.AU","BK7067","SGXZ23171101.USD","CVB.AU","NEU.AU","XKO.AU","BK7502","IMM.AU","SG9999004303.SGD","XAO.AU","CSL.AU","BK7007","LU1169589451.USD","DXB.AU","LU1169590202.USD","BOT.AU","BK4086","CSL","LU0728928796.USD","BK7511","TLX.AU","BK7508","SNT.AU","BK7501","BK7096","XJO.AU"],"gpt_icon":0},{"id":"2479676827","title":"Curvebeam AI Ltd-Placement - Cleansing Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2479676827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479676827?lang=en_us&edition=full_marsco","pubTime":"2024-10-31 06:20","pubTimestamp":1730326857,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUEBJ0PVF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","CVB.AU"],"gpt_icon":0}],"profile":{"websiteUrl":"http://curvebeamai.com","stockEarnings":[{"period":"1week","weight":-0.0476},{"period":"1month","weight":-0.1667},{"period":"3month","weight":-0.0909},{"period":"6month","weight":-0.0909},{"period":"1year","weight":-0.3939},{"period":"ytd","weight":-0.2593}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":-0.0169},{"period":"3month","weight":0.0469},{"period":"6month","weight":0.095},{"period":"1year","weight":0.1651},{"period":"ytd","weight":0.0889}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"exchange":"ASX","name":"CurveBeam AI Limited","nameEN":"CurveBeam AI Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CurveBeam AI Limited(CVB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CurveBeam AI Limited(CVB.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CurveBeam AI Limited,CVB.AU,CurveBeam AI Limited股票,CurveBeam AI Limited股票老虎,CurveBeam AI Limited股票老虎国际,CurveBeam AI Limited行情,CurveBeam AI Limited股票行情,CurveBeam AI Limited股价,CurveBeam AI Limited股市,CurveBeam AI Limited股票价格,CurveBeam AI Limited股票交易,CurveBeam AI Limited股票购买,CurveBeam AI Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CurveBeam AI Limited(CVB.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CurveBeam AI Limited(CVB.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction